ExploreWatchlistsPricing
  1. JP-listed companies
  2. SymBio Pharmaceuticals Limited
  3. Financials
  4. Gross profit

SymBio Pharmaceuticals Limited (4582)

Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Dec 31, 2025947-49.43%
Dec 31, 20241,873-57.53%
Dec 31, 20234,411-41.96%
Dec 31, 20227,600+30.93%
Dec 31, 20215,804+569.60%
Dec 31, 2020867+0.24%
Dec 31, 2019865-26.27%
Dec 31, 20181,173+13.73%
Dec 31, 20171,031+14.05%
Dec 31, 2016904+55.09%
Dec 31, 2015583+10.70%
Dec 31, 2014527

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat